Literature DB >> 7680544

The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine.

P S Randhawa1, R Shapiro, M L Jordan, T E Starzl, A J Demetris.   

Abstract

The histopathological changes in 51 renal allograft biopsies from patients immunosuppressed with FK506 were compared with those seen in 30 needle biopsies obtained from patients on cyclosporine. The frequency and severity of rejection episodes were similar in both groups. Tubular vacuolation and myocyte vacuolation were found to be useful morphological markers to monitor short-term drug toxicity associated with both drugs. Long-term administration of FK506 led to striped interstitial fibrosis and arteriolar hyalinosis, similar to that previously documented for cyclosporine. One case each of hemolytic uremic syndrome and necrotizing arteriopathy was noted in patients receiving FK506. FK506 and cyclosporine are structurally unrelated compounds; hence the parallelism observed in their nephrotoxicity profile suggests that the interactions of these drugs with renal tissue involves the operation of two different initial signal-transducing mechanisms, ultimately activating the same final metabolic pathways.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7680544      PMCID: PMC3229279          DOI: 10.1097/00000478-199301000-00007

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  33 in total

1.  The mechanism of action of FK 506.

Authors:  J E Kay; A L Moore; S E Doe; C R Benzie; R Schönbrunner; F X Schmid; A P Halestrap
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

2.  The effect of FK 506 and CyA on the Lewis rat renal ischemia model.

Authors:  M A Nalesnik; H S Lai; N Murase; S Todo; T E Starzl
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

3.  Cyclosporine and FK 506 induced inhibition of renal epithelial cell proliferation.

Authors:  J McCauley; Z Farkus; S J Prasad; H A Plummer; S A Murray
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

4.  FK 506 is a direct glomeruloconstrictor, as determined by electrical resistance pulse sizing (ERPS).

Authors:  K V Lieberman; W G Lin; L Reisman
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

5.  FK 506 conversion of renal allografts failing cyclosporine immunosuppression.

Authors:  M L Jordan; R Shapiro; C W Jensen; V Scantlebury; J Fung; A Tzakis; J McCauley; A Jain; J Demetrius; P Randhawa
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

6.  FK 506, rapamycin, and cyclosporine: effects on IL-4 and IL-10 mRNA levels in a T-helper 2 cell line.

Authors:  S C Wang; A Zeevi; M L Jordan; R L Simmons; D J Tweardy
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

7.  Urinary proteins as a marker of drug-induced renal damage following treatment with cyclosporine or FK 506.

Authors:  M Hossein-Nia; J J Devlin; M Fagbohun; J M Tredger; R Williams; A Johnston; D W Holt
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

8.  Disruption of renal function and gene expression by FK 506 and cyclosporine.

Authors:  S M Morris; D Kepka-Lenhart; N P Curthoys; R L McGill; R J Marcus; S Adler
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

9.  Hemolytic-uremic syndrome in a renal transplant recipient on FK 506 immunosuppression.

Authors:  R J Schmidt; K K Venkat; F Dumler
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

10.  Histopathology of human renal allograft rejection under FK 506: a comparison with cyclosporine.

Authors:  A J Demetris; B Banner; J Fung; R Shapiro; M Jordan; T E Starzl
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

View more
  35 in total

1.  Adult heart transplantation under tacrolimus (FK506) immunosuppression: histopathologic observations and comparison to a cyclosporine-based regimen with lympholytic (ATG) induction.

Authors:  A C Tsamandas; S M Pham; E C Seaberg; O Pappo; R L Kormos; A Kawai; B P Griffith; A Zeevi; R Duquesnoy; J J Fung; T E Starzl; A J Demetris
Journal:  J Heart Lung Transplant       Date:  1997-07       Impact factor: 10.247

2.  A prospective, randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone in renal transplant patients.

Authors:  R Shapiro; M L Jordan; V P Scantlebury; C Vivas; J J Fung; J McCauley; P Randhawa; A J Demetris; W Irish; A Jain
Journal:  Transplant Proc       Date:  1995-02       Impact factor: 1.066

3.  Tacrolimus (FK506)-Associated Renal Pathology.

Authors:  Parmjeet S Randhawa; Thomas E Starzl; Anthony Jake Demetris
Journal:  Adv Anat Pathol       Date:  1997-07       Impact factor: 3.875

4.  Microvascular changes in renal allografts associated with FK506 (Tacrolimus) therapy.

Authors:  P S Randhawa; A C Tsamandas; M Magnone; M Jordan; R Shapiro; T E Starzl; A J Demetris
Journal:  Am J Surg Pathol       Date:  1996-03       Impact factor: 6.394

5.  Tacrolimus in pediatric renal transplantation.

Authors:  R Shapiro; V P Scantlebury; M L Jordan; C Vivas; H A Gritsch; D Ellis; N Gilboa; S Lombardozzi-Lane; W Irish; J J Fung; T R Hakala; R L Simmons; T E Starzl
Journal:  Transplantation       Date:  1996-12-27       Impact factor: 4.939

6.  Renal transplantation at the University of Pittsburgh: the impact of FK506.

Authors:  R Shapiro; M Jordan; V P Scantlebury; C Vivas; H A Gritsch; A S Rao; M Trucco; A Zeevi; A J Demetris; P Randhawa
Journal:  Clin Transpl       Date:  1994

Review 7.  Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation.

Authors:  D H Peters; A Fitton; G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

Review 8.  Clinical use of tacrolimus (FK-506) in infants and children with renal transplants.

Authors:  D Ellis
Journal:  Pediatr Nephrol       Date:  1995-08       Impact factor: 3.714

9.  Influence of conversion from calcineurin inhibitors to everolimus on fibrosis, inflammation, tubular damage and vascular function in renal transplant patients.

Authors:  Nadir Alpay; Abdullah Ozkok; Yasar Caliskan; Tulin Akagun; Suzan Adın Cinar; Gunnur Deniz; Muzaffer Sariyar; Alaattin Yildiz
Journal:  Clin Exp Nephrol       Date:  2014-02-11       Impact factor: 2.801

10.  Race, Calcineurin Inhibitor Exposure, and Renal Function After Solid Organ Transplantation.

Authors:  L Yessayan; A Shafiq; E Peterson; K Wells; Y Hu; L K Williams; D Lanfear
Journal:  Transplant Proc       Date:  2015-12       Impact factor: 1.066

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.